- Home
- IVP vs ZVSA Comparison
IVP vs ZVSA Comparison
Compare IVP & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- ZVSA
- Stock Information
- Founded
- IVP 2020
- ZVSA 2014
- Country
- IVP United States
- ZVSA United States
- Employees
- IVP N/A
- ZVSA N/A
- Industry
- IVP Diversified Commercial Services
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- ZVSA Health Care
- Exchange
- IVP Nasdaq
- ZVSA Nasdaq
- Market Cap
- IVP 3.3M
- ZVSA 3.0M
- IPO Year
- IVP 2023
- ZVSA N/A
- Fundamental
- Price
- IVP $0.97
- ZVSA $0.59
- Analyst Decision
- IVP
- ZVSA
- Analyst Count
- IVP 0
- ZVSA 0
- Target Price
- IVP N/A
- ZVSA N/A
- AVG Volume (30 Days)
- IVP 74.7K
- ZVSA 11.7M
- Earning Date
- IVP 08-13-2025
- ZVSA 08-08-2025
- Dividend Yield
- IVP N/A
- ZVSA N/A
- EPS Growth
- IVP N/A
- ZVSA N/A
- EPS
- IVP N/A
- ZVSA N/A
- Revenue
- IVP $15,399,751.00
- ZVSA N/A
- Revenue This Year
- IVP N/A
- ZVSA N/A
- Revenue Next Year
- IVP N/A
- ZVSA N/A
- P/E Ratio
- IVP N/A
- ZVSA N/A
- Revenue Growth
- IVP N/A
- ZVSA N/A
- 52 Week Low
- IVP $0.90
- ZVSA $0.47
- 52 Week High
- IVP $401.50
- ZVSA $6.30
- Technical
- Relative Strength Index (RSI)
- IVP 24.79
- ZVSA 42.68
- Support Level
- IVP $1.58
- ZVSA $0.65
- Resistance Level
- IVP $1.76
- ZVSA $1.67
- Average True Range (ATR)
- IVP 0.14
- ZVSA 0.13
- MACD
- IVP -0.07
- ZVSA -0.01
- Stochastic Oscillator
- IVP 7.85
- ZVSA 1.05
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.